Utilising Quantum Machine Learning and quantum computing for genomic research and development

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: 10083188

Grant search

Key facts

  • Disease

    Disease X
  • Start & end year

    2023
    2023
  • Known Financial Commitments (USD)

    $151,124.28
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    David Curry
  • Research Location

    United Kingdom
  • Lead Research Institution

    QUANTUM BASE ALPHA LTD
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Quantum Base Alpha is working with the University of Edinburgh and the Medicines Discovery Catapult to utilise the potential of Quantum Computing (QC) together with Quantum Machine Learning (QML)to help the UK government department DHSC enhance medicine discovery. The project's focus is using advanced QML bioinformatics tools to study the genomics of pathogens. Genomics can be thought of as the fragmentation, sequencing, and reassembly of DNA to generate a full computational representation of this DNA. It is a cornerstone of modern medicine and biological science and research. Genomics is a rapidly growing market segment and is essential in future drug discovery. It has been shown statistically that DNA has many similarities to human languages and classic Machine Learning transformer models have given promising results in this field. QBA will incorporate quantum computing into these classic machine learning approaches to study the pathogens and suggest ncDNA regions for drug development. This should provide a quantum advantage in fidelity, accuracy and computational cost. Our intention is to create a quantum computational platform that supports the identification of disease-relevant functional regions within ncDNA sequences and develop applications against Disease X and future epidemics.